Literature DB >> 26124343

Expression of EMT Markers SLUG and TWIST in Breast Cancer.

Jedrzej Grzegrzolka1, Martyna Biala1, Patrycja Wojtyra1, Christopher Kobierzycki2, Mateusz Olbromski1, Agnieszka Gomulkiewicz1, Aleksandra Piotrowska1, Janusz Rys3, Marzena Podhorska-Okolow1, Piotr Dziegiel4.   

Abstract

BACKGROUND: The epithelial-mesenchymal transition (EMT) has been observed in progression of in situ breast cancer to the invasive form and might be initiated by snail family zinc finger 2 (SLUG) and twist family bHLH transcription factor 1 (TWIST) protein overexpression. During this phenomenon, cells lose their epithelial phenotype and acquire mesenchymal features. The aim of the study was to examine the association of EMT markers SLUG and TWIST with clinicopathological data and the possibility of using these proteins as prognostic markers of breast cancer.
MATERIALS AND METHODS: Immunohistochemical analysis (IHC) of SLUG and TWIST expression was performed on archival paraffin samples of 19 cases with fibrocystic breast changes (control group), 148 cases of invasive ductal breast cancer (IDC) and 26 of invasive lobular breast cancer (ILC). Laser capture microdissection for isolation of cells from 17 frozen samples of IDC was employed and subsequently SLUG and TWIST mRNA expression in cancer and stromal cells was detected separately by real-time polymerase chain reaction.
RESULTS: SLUG and TWIST expression in IDC was significant higher in stromal cells regardless of the method of quantification used (p<0.001 for SLUG mRNA, and p<0.0001 for SLUG IHC, TWIST IHC and TWIST mRNA expression). Positive correlation of SLUG and TWIST protein and mRNA expression was observed in stromal cells of IDC (r=0.347; p<0.0001 and r=0.704; p<0.01, respectively). Expression of TWIST protein in IDC was higher in cancer cells of cases with shorter event-free survival period, as well as in stromal cells of cases with shorter overall survival period (p<0.05 for both).
CONCLUSION: Stromal cells could play a role in the regulation of EMT in breast cancer. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  EMT; SLUG; TWIST; breast cancer; epithelial-mesenchymal transition

Mesh:

Substances:

Year:  2015        PMID: 26124343

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  24 in total

1.  Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-κB/p65 signaling pathway.

Authors:  Eslam A Elghonaimy; Sherif A Ibrahim; Amal Youns; Zeinab Hussein; Mohamed Akram Nouh; Tahani El-Mamlouk; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Tumour Biol       Date:  2016-06-22

2.  A novel Twist1/hsa-miR138-5p/caspase-3 pathway regulates cell proliferation and apoptosis of human multiple myeloma.

Authors:  Wenjiao Qin; Qin Liu; Xiaoping Xu; Aiping Liu; Huating Zhang; Jingwen Gu; Tao Zhang
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

3.  LncRNA FTX Promotes Colorectal Cancer Cells Migration and Invasion by miRNA-590-5p/RBPJ Axis.

Authors:  Guo-Qun Chen; Zhi-Ming Liao; Jiao Liu; Fang Li; Da Huang; Ya-Dong Zhou
Journal:  Biochem Genet       Date:  2021-01-03       Impact factor: 1.890

4.  ETS1 regulates Twist1 transcription in a KrasG12D/Lkb1-/- metastatic lung tumor model of non-small cell lung cancer.

Authors:  Guetchyn Millien; Yuxia Cao; Carl J O'Hara; Jean-Bosco Tagne; Anne Hinds; Mary C Williams; Maria I Ramirez; Hasmeena Kathuria
Journal:  Clin Exp Metastasis       Date:  2018-06-16       Impact factor: 5.150

5.  The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.

Authors:  Hong-Jen Lee; Chien-Feng Li; Diane Ruan; Scott Powers; Patricia A Thompson; Michael A Frohman; Chia-Hsin Chan
Journal:  Mol Cell       Date:  2016-09-08       Impact factor: 17.970

Review 6.  TWIST1 and BMI1 in Cancer Metastasis and Chemoresistance.

Authors:  Hong Ren; Peizhun Du; Zongyu Ge; Yiting Jin; Di Ding; Xiuping Liu; Qiang Zou
Journal:  J Cancer       Date:  2016-05-25       Impact factor: 4.207

Review 7.  Novel Molecular Markers for Breast Cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Biomark Cancer       Date:  2016-03-13

8.  Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.

Authors:  Weiqiang Qiao; Zhiqiang Jia; Heyang Liu; Qipeng Liu; Ting Zhang; Wanying Guo; Peng Li; Miao Deng; Sanqiang Li
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

9.  Jazf1 promotes prostate cancer progression by activating JNK/Slug.

Authors:  Yonghun Sung; Song Park; Si Jun Park; Jain Jeong; Minjee Choi; Jinhee Lee; Wookbong Kwon; Soyoung Jang; Mee-Hyun Lee; Dong Joon Kim; Kangdong Liu; Sung-Hyun Kim; Jae-Ho Lee; Yun-Sok Ha; Tae Gyun Kwon; Sanggyu Lee; Zigang Dong; Zae Young Ryoo; Myoung Ok Kim
Journal:  Oncotarget       Date:  2017-12-12

10.  Synergetic Effects of Intronic Mature miR-944 and ΔNp63 Isoforms on Tumorigenesis in a Cervical Cancer Cell Line.

Authors:  Jungho Kim; Sunyoung Park; Yunhee Chang; Kwang Hwa Park; Hyeyoung Lee
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.